drugset
drugset / Trial / NCT00027716

Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

NCT00027716 ↗

Phase 2 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Bortezomib may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have advanced or metastatic sarcoma.

Timeline

Start
2001-10
Primary completion
2004-05
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule — Intravenous

Indications

sarcoma